Adjuvant regional nodal irradiation did not improve outcomes in T1-2N1 breast cancer after breast-conserving surgery: A propensity score matching analysis of BIG02/98 and BCIRG005 trials

Wei-Xiang Qi, Lu Cao, Cheng Xu, Shengguang Zhao, Jiayi Chen, Wei-Xiang Qi, Lu Cao, Cheng Xu, Shengguang Zhao, Jiayi Chen

Abstract

Aim: To determine whether the addition of regional nodal irradiation (RNI) to whole-breast irradiation (WBI) would improve outcomes over WBI alone in T1-2N1 breast cancer after breast-conserving surgery (BCS) and adjuvant systematic therapy.

Methods: Data were obtained from two randomized controlled trials (NCT00174655 and NCT00312208). Univariate and multivariate Cox-regression analysis were performed to investigate predictors for overall survival and disease-free survival. A 1:1 propensity score matching (PSM) analysis was applied to eliminate selection bias.

Results: With median follow-up 80 months (range: 3-155 months), the 5-year local regional recurrence in the WBI group was 2% vs. 5% (p = 0.28) in the WBI + supraclavicular radiotherapy, and the rate of 5-year distant metastasis in the WBI group was 7% vs. 13% in the WBI + supraclavicular radiotherapy (p = 0.0748); In addition, the 5-year local regional recurrence in the WBI group was 3% vs. 9% (p = 0.19) in the WBI + internal mammary irradiation (IMI); However, the rate of 5-year distant metastasis in the in the WBI group was significantly lower than that in the WBI + IMI (8% vs. 24%, p = 0.036). After PSM, cox-regression analysis indicated that neither RNI nor IMI in combination with WBI in T1-2N1 breast cancer was associated with an improved overall survival and disease-free survival when compared to WBI alone.

Conclusion: The addition of RNI to WBI in T1-2N1 breast cancer after BCS and adjuvant systematic therapy did not improve outcomes in comparison with WBI alone. Further studies are still needed to identify patients who would most benefit from RNI in this patient population.

Keywords: Breast cancer; Breast conserving surgery; Propensity score matching analysis; Regional nodal irradiation; T1-2N1.

Conflict of interest statement

Declaration of competing interest None.

Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
cumulative incidence of local-regional recurrence and distant metastasis according to regional nodal irradiation
Fig. 2
Fig. 2
overall survival and disease-free survival according to regional nodal irradiation

References

    1. Voogd A.C., Nielsen M., Peterse J.L., Blichert-Toft M., Bartelink H., Overgaard M., van Tienhoven G., Andersen K.W., Sylvester R.J., van Dongen J.A. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol : Off J Am Soc Clin Oncol. 2001;19(6):1688–1697.
    1. Pazos M., Schonecker S., Reitz D., Rogowski P., Niyazi M., Alongi F., Matuschek C., Braun M., Harbeck N., Belka C. Recent developments in radiation oncology: an overview of individualised treatment strategies in breast cancer. Breast Care. 2018;13(4):285–291.
    1. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R., Jeong J.H., Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–1241.
    1. Early Breast Cancer Trialists’ Collaborative G., Darby S., McGale P., Correa C., Taylor C., Arriagada R., Clarke M., Cutter D., Davies C., Ewertz M. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–1716.
    1. Avisar E. A tailored approach to regional nodal irradiation. Breast Canc Res Treat. 2016;155(1):1–2.
    1. Kim J., Chang J.S., Choi S.H., Kim Y.B., Keum K.C., Suh C.O., Yang G., Cho Y., Kim J.W., Lee I.J. Radiotherapy for initial clinically positive internal mammary nodes in breast cancer. Radiat Oncol J. 2019;37(2):91–100.
    1. Kim K., Jeong Y., Shin K.H., Kim J.H., Ahn S.D., Kim S.S., Suh C.O., Kim Y.B., Choi D.H., Park W. official journal of Korean Cancer Association; 2019. Impact of regional nodal irradiation for breast cancer patients with supraclavicular and/or internal mammary lymph node involvement: a multicenter, retrospective study (KROG 16-14). Cancer research and treatment.
    1. Poortmans P.M., Collette S., Kirkove C., Van Limbergen E., Budach V., Struikmans H., Collette L., Fourquet A., Maingon P., Valli M. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–327.
    1. Abdel-Rahman O. Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease : an individual patient data analysis of three clinical trials. Strahlenther Onkol : Organ der Dtsch Rontgengesellschaft [et al] 2019;195(4):297–305.
    1. Zeidan Y.H., Habib J.G., Ameye L., Paesmans M., de Azambuja E., Gelber R.D., Campbell I., Nordenskjold B., Gutierez J., Anderson M. Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: analysis of the breast international group 02-98 trial. Int J Radiat Oncol Biol Phys. 2018;101(2):316–324.
    1. Thomas J.S., Hanby A.M., Russell N., van Tienhoven G., Riddle K., Anderson N., Cameron D.A., Bartlett J.M., Piper T., Cunningham C. The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer. Breast Canc Res Treat. 2017;163(1):63–69.
    1. Mackey J.R., Pienkowski T., Crown J., Sadeghi S., Martin M., Chan A., Saleh M., Sehdev S., Provencher L., Semiglazov V. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol : Off J Eur Soc Med Oncol/ESMO. 2016;27(6):1041–1047.
    1. Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., Rouas G., Francis P., Crown J.P., Hitre E. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(7):860–867.
    1. Fernandez-Cuesta L., Oakman C., Falagan-Lotsch P., Smoth K.S., Quinaux E., Buyse M., Dolci M.S., Azambuja E.D., Hainaut P., Dell’orto P. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res. 2012;14(3):R70.
    1. Reintgen C., Reintgen D., Solin L.J. Advances in local-regional treatment for patients with early-stage breast cancer: a review of the field. Clin Breast Canc. 2010;10(3):180–187.
    1. Whelan T.J., Olivotto I.A., Parulekar W.R., Ackerman I., Chua B.H., Nabid A., Vallis K.A., White J.R., Rousseau P., Fortin A. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–316.
    1. Litton J.K., Scoggins M.E., Hess K.R., Adrada B.E., Murthy R.K., Damodaran S., DeSnyder S.M., Brewster A.M., Barcenas C.H., Valero V. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol : Off J Am Soc Clin Oncol. 2019
    1. van Ramshorst M.S., van der Voort A., van Werkhoven E.D., Mandjes I.A., Kemper I., Dezentje V.O., Oving I.M., Honkoop A.H., Tick L.W., van de Wouw A.J. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–1640.
    1. Cao L., Ou D., Shen K.W., Cai G., Cai R., Xu F., Zhao S.G., Xu C., Grellier Adedjouma N., Kirova Y.M. Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer. Cancer Radiother. 2018;22(1):38–44.
    1. Cao L., Xu C., Kirova Y.M., Cai G., Cai R., Wang S.B., Shen K.W., Ou D., Chen J.Y. The role of the neo-bioscore staging system in guiding the optimal strategies for regional nodal irradiation following neoadjuvant treatment in breast cancer patients with cN1 and ypN0-1. Ann Surg Oncol. 2019;26(2):343–355.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner